CTOs on the Move


 
Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture™ (IRC™) technology, Atreca has an unparalleled insight into how cancer patients` immune responses can drive better clinical outcomes. Atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today`s patients is the key to creating a new generation of therapies. Atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.atreca.com
  • 500 Saginaw Drive First Floor
    Redwood City, CA USA 94063
  • Phone: 650.595.2595

Executives

Name Title Contact Details

Funding

Atreca raised $56M on 11/04/2015
Atreca raised $35M on 08/17/2017
Atreca raised $125M on 09/12/2018

Similar Companies

Altea Therapeutics Corporation

Altea Therapeutics Corporation is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prodesse

Prodesse is a Waukesha, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XTL Biopharmaceuticals

XTL Biopharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carmot Therapeutics

Carmot Therapeutics, Inc. is a biotech company focused on the discovery of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation. Carmot`s vision is to become a leader in drug discovery by unlocking novel therapeutic target space not currently accessible to conventional small molecule technologies.

Nohla Therapeutics

Nohla Therapeutics is a cellular therapy company driven to provide leading off the shelf therapies for patients with critical diseases. Nohla’s first product is a universal donor cell therapy targeting hematopoietic recovery and chemotherapy induced neutropenia, and is being extended to treat a range of other medical indications. This and other products in the pipeline are based on a unique umbilical cord blood expansion platform developed at the Fred Hutchinson Cancer Research Center